Navigation Links
Kiadis Pharma Receives IND Approval From FDA to Start Pivotal Clinical Trial With ATIR(TM) in the United States
Date:7/8/2010

AMSTERDAM, July 8 /PRNewswire/ -- Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR™ in the United States.  Kiadis Pharma is currently enrolling patients in a multinational, pivotal clinical study at hospitals in Europe and Canada.  With the approval of the IND, US hospitals will also participate in this study.

ATIR™ is designed for blood cancer patients in need of allogeneic bone marrow transplantation, who do not have a matched donor available.  ATIR™ allows a mismatched family member to act as donor, and is being developed to reduce Transplant Related Mortality without inducing Graft versus Host Disease (GvHD).

"We are very encouraged by this IND approval received from the FDA. We look forward to starting treatment of US patients in our ongoing multinational, pivotal clinical study, in which patients in Europe and Canada are already being treated," commented Manja Bouman, CEO of Kiadis Pharma.

ATIR™ has shown excellent clinical results in a phase I/II study in patients who received a haploidentical mismatched bone marrow transplantation from a family member donor.  The two year follow up data showed no Transplant Related Mortality (TRM) and overall survival of 70% in a group of high risk leukemia patients who received an efficacious dose of ATIR™.  These results compare favorably to outcomes of bone marrow transplantations from a ful
'/>"/>

SOURCE Kiadis Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
2. Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany
3. Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations
4. Kiadis Pharma Receives Two Orphan Drug Designations for Reviroc(TM) From the FDA
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015  ANI Pharmaceuticals, ... announced that it has acquired the approved abbreviated ... USP 50mg, 100mg and 150mg, previously marketed by ... market for this product was approximately $39 million ... Przybyl , President and CEO of ANI Pharmaceuticals, ...
(Date:3/5/2015)... DUBLIN , Mar. 05, 2015 Research and ... addition of the "Japan Pharma Outlook 2015: Year ... Overseas Strategic Initiatives" report to their offering. ... Japan from April -2014 (Annexure 1) ... the companies - whether generic or innovator. The most ...
(Date:3/5/2015)... -- Hitachi Medical Systems Europe is ... *    at ECR 2015 - the open high-field ... benchmark for patient-centric care. The new features of OASIS ... workflow management and costs. OASIS demonstrates the high levels ... in Neurology, Orthopaedics, Paediatrics, Oncology, Vascular and General Imaging, ...
Breaking Medicine Technology:ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 2Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 3Hitachi Medical Systems Europe Launches the New Generation of OASIS*- The World's Most Powerful Open High-Field 1.2T MRI - A New Level in Patient-Centric Care 2Hitachi Medical Systems Europe Launches the New Generation of OASIS*- The World's Most Powerful Open High-Field 1.2T MRI - A New Level in Patient-Centric Care 3
(Date:3/5/2015)... Venice, FL (PRWEB) March 05, 2015 ... their 15th annual listing of “Pros to Know” in ... announce that two members of MEBC’s leadership team were ... Rhodes were nominated and received this award due to ... use of innovative methods for meeting and resolving client ...
(Date:3/5/2015)... March 05, 2015 Dr. Jonathan Glashow ... http://www.orthopedicsurgeonnyc.com ) has been named by Castle Connolly ... Metro area. Dr. Glashow has been selected by Castle ... to the top specialty care doctors in the tri-state ... Castle Connolly program, which carefully screens and selects doctors ...
(Date:3/5/2015)... March 05, 2015 As a ... (AAPA) review of Clearstream, LLC ’s products, ... Clearstream’s MediDefense line of products—led by their mPulse ... Affinity Partner Program. , The AAPA—which represents a ... all medical and surgical specialties in the U.S.—advocates ...
(Date:3/5/2015)... San Diego, CA (PRWEB) March 05, 2015 ... that it is now running on 100% pollution-free ... provider, Arcadia Power. , As an Arcadia ... Environmental Protection Agency’s (EPA) Green Power Partnership requirements, ... and Starbucks that also purchase clean energy. Earth ...
(Date:3/5/2015)... 05, 2015 The Journal of ... a special issue devoted entirely to ... PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococci) ... reaction triggered by infections such as strep throat, ... inflammation of the child's brain. This inflammation causes ...
Breaking Medicine News(10 mins):Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3
... The California Institute for Quantitative Biosciences (QB3) has entered ... in its efforts to convert bioscience innovation into a ... Deloitte, which provides consulting, audit, tax and financial ... to help QB3 develop an "innovation ecosystem," bringing together ...
... has often been associated with serious side-effects. Researchers at ... in mice, found a way of utilising the positive ... skeleton is acted on, current research at the Academy ... journal PNAS (Proceedings of the National Academy of Sciences). ...
... reveal your risk of a future heart attack, and it ... detail thanks to a new technique which could eventually be ... a thesis from the University of Gothenburg, Sweden. Atherosclerosis ... of future heart disease, and it is therefore important to ...
... 11) --A study from Tufts Medical Center researchers published today ... patients who have few other options because their disease has ... Cancer Cell, the study is the first published ... (CML) in a mouse model of the disease and is ...
... Salamon HealthDay Reporter , MONDAY, April 11 ... than their peers who don,t have children, and they ... calories, a new study suggests. Examining data from ... Adults), researchers from the University of Minnesota focused on ...
... MONDAY, April 11 (HealthDay News) -- The tone of ... claims a study that challenges previous research suggesting the ... Texas A&M University assessed 175 voice samples provided by ... and found that there were no changes in eight ...
Cached Medicine News:Health News:QB3, Deloitte collaborate to drive California bioscience innovation 2Health News:New potential atherosclerosis risk marker discovered 2Health News:New drug shows potential for treatment-resistant leukemia 2Health News:Having Kids Might Make Young Women Heavier, Less Fit 2Health News:Having Kids Might Make Young Women Heavier, Less Fit 3
Inquire...
... 6-Place Rotor has a standard 1.5ml rotor and ... adapters. Easy operation (no switches to mess with). ... press the plastic tab to open. Starts and ... and 2000 x g. Only five inches in ...
Inquire...
Inquire...
Medicine Products: